Science & Solutions

Looking to the Future in Cardiovascular Treatment

More than 10 years of experience in lipid management prepared Jeremy Smart, PharmD, BCPS, CLS for his role at Sanofi as a Medical Liaison for the cardiovascular team.

As a Medical Science Liaison on the cardiovascular (CV) team at Sanofi, I spend nearly all of my time speaking with physicians about high cholesterol and CV disease. I’m lucky to have a job I love, in a field where I can make an impact on the health of patients, and the care they receive.

Having formerly run a lipid clinic, where patients with high cholesterol or lipid levels can go for specialized support and treatment, I understand the physicians’ perspective when it comes to caring for patients with CV disease or high low-density lipoprotein (LDL) cholesterol (also known as “bad” cholesterol). I know firsthand how exasperating it can be when they think they’ve run out of options to help reach their heart health goal, especially knowing one in every four deaths in the U.S. is a result of heart disease.1

Jeremy Smart

For that reason, I was drawn to clinical trials – it helped me get a glimpse into the next generation of high LDL-C treatment. My career at Sanofi began shortly after my clinic participated in one of Sanofi’s clinical trials, and I was able to leverage my experience recruiting patients for clinical trials to better assist physicians at institutions involved in Sanofi clinical trials.

When I support physicians on clinical trial recruitment, I often think back to a former patient of mine who had a family history of CV disease who struggled to get to her LDL cholesterol goal. After prescribing several available treatments, we were both frustrated that nothing seemed to be working and thought there were no other treatment options available to her at that time.

That changed when my clinic was approached to participate in a study involving a potential new medication that could help her condition. I learned more about the potential of this novel agent and reached out to my former patient. She had moved but was interested in the idea of joining a clinical trial, so I helped her enroll in a study location near her home. Today, this patient who thought she had no hope, has been able to better manage her disorder.

I feel fortunate to be given an opportunity to help patients affected by CV disease, and to work with a team that shares my passion for helping these patients. Since joining Sanofi CV Medical Affairs, I’m continually impressed by its culture of innovation, open mindedness, humility, comradery and teamwork – all of which help us work towards our shared goal of ensuring patients get the treatment they need.

In fact, when I think of my team and the work we do, I am reminded of a quote by Harry Truman: “It’s amazing what you can accomplish if you do not care who gets the credit.” I truly feel this applies to the Sanofi CV Medical Affairs team.

Looking to the future, I am excited to see what the continued innovation of the CV space brings when it comes to potential new treatment options, and how our team at Sanofi can help bring these innovations to the patients who need them most.

  1. Centers for Disease Control and Prevention. Heart Disease Facts. Accessed March 2018.